CCR2 and CCR5 genes polymorphisms in women with cervical lesions from Pernambuco, Northeast Region of Brazil: a case-control study

Santos, Erinaldo Ubirajara Damasceno dos; Lima, Géssica Dayane Cordeiro de; Oliveira, Micheline de Lucena; Heráclio, Sandra de Andrade; Silva, Hildson Dornelas Angelo da; Crovella, Sérgio; Maia, Maria de Mascena Diniz; Souza, Paulo Roberto Eleutério de

doi:10.1590/0074-02760150367

Cited by 12 publications

(18 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, over 30 genes have been studied for their role in cervical cancer risk and these include, Bid, BRIP1, Caspase 8, CCR2, CTLA4, CYP1A1, EXO1, FASLG, FASR, HOTAIR, IFN gamma, PARP1, XRCC1, MDM2, IL10, IL12, HLA B/C, MTHFR, Tap2, TNF-a, TLR9, p16, PIK3CA, p21, and p53 Martínez-Nava et al, 2016;Mehta et al, 2015;Mei et al, 2014;Dos Santos et al, 2016;Sousa et al, 2011;Tsakogiannis et al, 2017;and Wang et al, 2017). Of these, genes only nine have been researched in African populations, highlighting a big gap in cervical cancer molecular epidemiology studies in a continent where 90% of the cervical cancer-related deaths are predicted (MboubaBouassa et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

“…Current reports show the involvement of Caspase 8, CCR2, CTLA4, CYP1A1, EXO1, FASLG, FASR, HOTAIR, IFN gamma, PARP1, XRCC1, MDM2, IL10, IL12, HLA B/C, MTHFR, Tap2, TNF-a, TLR9, p16, PIK3CA, and p21 in cervical susceptibility (Alanazi et al, 2013;Barbisan et al, 2012;Chang et al, 2015;Jin et al, 2017;Ma et al, 2013;Martínez-Nava et al, 2016;Mehta et al, 2015;Mei et al, 2014;Piccolo and Crispi, 2012;Roszack et al, 2014;Dos Santos et al, 2016;Sousa et al, 2011;Tsakogiannis et al, 2017;Wang et al, 2017;and Zhuo et al, 2014). However, these findings have mostly been corroborated in Caucasian and Asian populations, and only a few have been reported on African populations.…”

Section: Genetics and Cervical Cancermentioning

confidence: 99%

“…The allelic frequency in Africans is 10% compared with 23.5% and 30% in Caucasians and Asians, respectively (Coelho et al, 2007;Su et al, 2000;Zheng et al, 2006). It was also reported that CCR2 V64I conferred a protective effect in the instance of HPV 16 infection in Brazilian women, therefore, it is feasible that the prevalence of HPV 16 plays a significant role in relation to the role of CCR2 V64I as a cervical cancer susceptibility marker (Dos Santos et al, 2016).…”

Section: Chemokine Receptormentioning

confidence: 99%

See 2 more Smart Citations

Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers?

Kuguyo

Tsikai

Thomford

et al. 2018

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

Human papillomavirus (HPV) is an essential but not a sufficient cervical cancer etiological factor. Cancer promoters, such as host genetic mutations, significantly modulate therapeutic responses and susceptibility. In cervical cancer, of interest have been viral clearing genes and HPV oncoprotein targets, for which conflicting data have been reported among different populations. This expert analysis evaluates cervical cancer genetic susceptibility biomarkers studied in African populations. Notably, the past decade has seen Africa as a hotbed of biomarker and precision medicine innovations, thus potentially informing worldwide biomarker development strategies. We conducted a critical literature search in PubMed/MEDLINE, Google Scholar, and Scopus databases for case-control studies reporting on cervical cancer genetic polymorphisms among Africans. We found that seven African countries conducted cervical cancer molecular epidemiology studies in one of Casp8, p53, CCR2, FASL, HLA, IL10, TGF-beta, and TNF-alpha genes. This analysis reveals a remarkable gap in cervical cancer molecular epidemiology among Africans, whereas cervical cancer continues to disproportionately have an impact on African populations. Genome-wide association, whole exome-and whole-genome sequencing studies confirmed the contribution of candidate genes in cervical cancer. With such advances and omics technologies, the role of genetic susceptibility biomarkers can be exploited to develop novel interventions to improve current screening, diagnostic and prognostic methods worldwide. Exploring these genetic variations is crucial because African populations are genetically diverse and some variants or their combined effects are yet to be discovered and translated into tangible clinical applications. Thus, translational medicine and flourishing system sciences in Africa warrant further emphasis in the coming decade.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Genetics and Cervical Cancermentioning

confidence: 99%

Section: Chemokine Receptormentioning

confidence: 99%

See 1 more Smart Citation

Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers?

Kuguyo

Tsikai

Thomford

et al. 2018

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

show abstract

“…CCR2, the receptor for MCP-1, play an important role in inflammatory disorders and some diseases [35, 36]. MCP-1/CCR2 signaling was involved in human crescentic glomerulonephrtitis and murine lupus nephritis [37, 38].…”

Section: Discussionmentioning

confidence: 99%

Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk

et al. 2016

View full text Add to dashboard Cite

Monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 stimulate inflammation response by activating and recruiting monocytes/macrophages. MCP-1 and CCR2 polymorphisms were reported to be associated with various diseases. To explore the relationship between MCP-1 and CCR2 polymorphisms and IgA nephropathy (IgAN), we conducted this case-control study by enrolling 351 IgAN patients and 310 health controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate potential associations of MCP-1 and CCR2 polymorphisms with susceptibility and clinical parameters of IgAN. No statistical differences between IgAN group and the control group in the MCP-1 -2518 and CCR2 +190 genotypic groups were observed (P > 0.05). Individuals with MCP-1 -2518 GG genotypes had a higher blood pressure (GG vs. AA+AG: OR = 1.79, 95% CI = 1.07-2.99, P = 0.026) and Lee's grade (GG vs. AA+AG: OR = 2.05, 95% CI = 1.19-3.54, P = 0.009; GG vs. AA: OR = 2.24, 95% CI = 1.19-4.20, P = 0.01), compared with patients with AA/AG genotypes. A significant association between CCR2 +190 polymorphism and Lee's grades was observed (GA+AA vs. GG: OR = 2.66, 95% CI = 1.63-4.35, P < 0.001; GA vs. AA+GG: OR = 2.27, 95% CI = 1.39-3.70, P = 0.001). Our results indicated that MCP-1 and CCR2 polymorphisms may influence the progression of IgAN, but not increase/decrease its susceptibility.

show abstract

“…Previous studies suggested that the polymorphism 190G > A of the CCR2 gene is associated with enhanced protection against HPV-16 infection [16]. Independent studies demonstrated the protective effect of CCR5 Δ32 in recovery from a HBV infection, and provided genetic epidemiological evidence for the role of CCR5 in the immune response to HBV [14,15].…”

Section: Introductionmentioning

confidence: 99%

Possible Impact of 190G > A CCR2 and Δ32 CCR5 Mutations on Decrease of the HBV Vaccine Immunogenicity—A Preliminary Report

Gańczak

Skonieczna-Żydecka

Drozd-Dąbrowska

et al. 2017

IJERPH

View full text Add to dashboard Cite

Background: Chemokine genetic variations are involved in infectious diseases such as hepatitis B virus (HBV). Several allelic variants might, in theory, affect the outcome of vaccination. Objectives: This study was carried out to examine the associations of Δ32 CCR5 and 190G > A CCR2 polymorphisms with a response to a primary course of three HBV vaccinations. Methods: Between December 2014 and December 2016, patients from three randomly selected primary care clinics in the West Pomeranian region (Poland), 1 month after receiving the third dose of HBV vaccine, were enrolled. Enzyme-linked immunosorbent assay (ELISA) system version 3.0 was used to detect anti-HBs and anti-HBc totals. The identification of polymorphisms were performed by a polymerase chain reaction technique using a single primer extension assay. Genotype distributions of responders versus non-responders to HBV vaccination were compared on the basis of anti-HBs level. Results: In 149 patients (mean age 60 years) the mean anti-HBs level was 652.2 ± 425.9 mIU/mL (range: 0–1111.0 mIU/mL). There were 14.1% (n = 21) non-responders to the HBV vaccine (anti-HBs < 10.0 mIU/mL). The wild type/Δ32 genotype of CCR5 gene was found in 18.1% participants, and 1.3% were Δ32/Δ32 homozygotes. The frequency of allele A of the CCR2 gene was 11.1%. Lower anti-HBs levels in Δ32/Δ32 homozygotes were observed (Me = 61 mIU/mL vs. Me = 660.2 mIU/mL; p = 0.048). As age was found to be a correlate to the anti-HBs titer (r = −0.218, p = 0.0075; 95% CI: −0.366–−0.059)—an analysis of a co-variance was performed which found a statistically significant (p = 0.04) difference in anti-HBs titres between Δ32/Δ32 homozygotes and other CCR5 genotypes. The association between anti-HBs titres and CCR2 genotypes was not statistically significant. Conclusions: Our study—which is a preliminary report that suggest this topic deserves further observation with larger sample sizes, different ethnicities, and other single nucleotide poly-morphisms (SNPs)—suggests the possible involvement of CCR5 polymorphism in impairing the immunologic response to HBV vaccination, predominantly in relation to the passage of time.

show abstract

CCR2 and CCR5 genes polymorphisms in women with cervical lesions from Pernambuco, Northeast Region of Brazil: a case-control study

Cited by 12 publications

References 44 publications

Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers?

Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers?

Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk

Possible Impact of 190G > A CCR2 and Δ32 CCR5 Mutations on Decrease of the HBV Vaccine Immunogenicity—A Preliminary Report

Contact Info

Product

Resources

About